V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 240002548 | 240002548 | 1.57 | 92.3 | Adjuvant (A) | 2018-01-26 | 2018-01-30 | CHOP R | N | N | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 101115927 |
| 240002552 | 240002552 | null | null | null | null | 2016-10-06 | AML MyeChild 01 IT Cyt | null | null | CHOP | 100131616 |
| 240002560 | 240002560 | 1.76 | 62.6 | Curative (C) | null | 2018-10-21 | ALL UKALL2011 Maintenance A1 | 02 | N | AML18 TRIAL | 100210667 |
| 240002567 | 240002567 | 1.81 | 91.3 | 03 | 2018-02-25 | 2018-02-26 | null | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 101621880 |
| 240002569 | 240002569 | null | null | null | null | 2018-12-26 | Hydroxycarbamide | null | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100645679 |
| 240002574 | 240002574 | 1.9 | 120.9 | Palliative (P) | null | 2019-06-23 | null | 02 | N | HYDROXYCARBAMIDE | 100213468 |
| 240002577 | 240002577 | 1.68 | 20.8 | 03 | null | 2016-12-10 | CYTARABINE + DAUNORUBICIN | N | Y | AML16 TRIAL | 101309020 |
| 240002578 | 240002578 | null | null | null | null | 2019-07-14 | Arsenic trioxide + Tretinoin | null | null | HYDROXYCARBAMIDE | 101858176 |
| 240002580 | 240002580 | 1.74 | 55.8 | Curative (C) | 2019-03-19 | 2019-03-19 | null | 02 | N | IMATINIB | 100624205 |
| 240002582 | 240002582 | 1.63 | 57.4 | Curative (C) | null | 2019-08-21 | CYTARABINE + DAUNORUBICIN + Gemtuzumab Ozogamicin | 02 | N | BENDAMUSTINE + RITUXIMAB | 100022375 |
| 240002584 | 240002584 | 1.74 | 60.5 | Curative (C) | null | 2017-11-17 | CHOP R | N | N | HYDROXYCARBAMIDE | 101292385 |
| 240002587 | 240002587 | null | null | null | null | 2018-04-15 | null | null | null | CABOZANTINIB | 100472245 |
| 240002602 | 240002602 | null | null | null | null | 2020-04-03 | AML 19 TRIAL | null | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100752562 |
| 240002611 | 240002611 | null | null | null | null | 2019-08-06 | CHOP R - 21 days | null | null | BORTEZOMIB + CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB | 101846368 |
| 240002616 | 240002616 | 1.87 | 105 | 03 | null | 2017-04-06 | Hydroxycarbamide | 02 | N | FLAG + IDARUBICIN | 100620403 |
| 240002622 | 240002622 | 1.66 | 0 | Curative (C) | null | 2019-07-21 | CHOP R | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100227102 |
| 240002623 | 240002623 | null | null | null | null | 2016-10-11 | CYTARABINE + DAUNORUBICIN | null | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 101568772 |
| 240002625 | 240002625 | 1.89 | 73.5 | Curative (C) | null | 2019-03-07 | null | 02 | N | HYDROXYCARBAMIDE | 101172769 |
| 240002632 | 240002632 | 0.96 | 64.25 | Curative (C) | null | 2016-03-04 | AML 18 TRIAL | 02 | N | DA | 100420743 |
| 240002635 | 240002635 | 1.67 | 73 | Curative (C) | null | 2019-03-16 | null | N | N | TRIPLE INTRATHECAL | 100372850 |
| 240002638 | 240002638 | 1.45 | 14 | Curative (C) | null | 2019-10-23 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 02 | N | FCR | 101711318 |
| 240002640 | 240002640 | null | null | null | null | 2018-08-30 | null | null | null | HYDROXYCARBAMIDE | 100049936 |
| 240002644 | 240002644 | null | null | null | null | 2016-12-02 | Trial Unspecified | null | null | UKALL2014 | 100290839 |
| 240002648 | 240002648 | 0 | 0 | 03 | 2018-01-14 | 2018-01-15 | Cytarabine Low Dose | null | N | CLADRIBINE | 100637437 |
| 240002651 | 240002651 | null | null | null | null | 2017-08-02 | Rituximab | null | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100487371 |
| 240002652 | 240002652 | 1.66 | 64.3 | Curative (C) | 2018-05-01 | 2018-05-02 | AML 18 TRIAL | 02 | N | DA | 100611346 |
| 240002654 | 240002654 | 1.64 | 83.2 | Curative (C) | null | 2018-05-15 | null | 02 | N | AML19 TRIAL | 100976932 |
| 240002664 | 240002664 | 1.83 | null | Curative (C) | 2016-09-26 | 2016-09-26 | null | 02 | N | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE | 101668404 |
| 240002667 | 240002667 | 1.67 | 76.35 | Curative (C) | 2018-06-19 | 2018-06-24 | DA | 02 | N | AML16 TRIAL | 100169468 |
| 240002683 | 240002683 | 1.53 | 100.7 | Palliative (P) | null | 2016-08-31 | null | N | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 101346341 |
| 240002687 | 240002687 | null | null | null | null | 2018-08-23 | DA | null | null | BORTEZOMIB + THALIDOMIDE | 101805483 |
| 240002691 | 240002691 | 0 | 71.5 | Curative (C) | 2018-02-26 | 2018-03-02 | AML Interim Guidelines FLA | 02 | N | CYTARABINE + DAUNORUBICIN + GEMTUZUMAB OZOGAMICIN | 101090800 |
| 240002696 | 240002696 | 1.71 | 72.2 | 03 | null | 2016-08-26 | DA | 02 | N | AML19 TRIAL | 101135032 |
| 240002699 | 240002699 | 1.65 | 78.15 | Curative (C) | null | 2016-05-16 | AML 19 TRIAL | 02 | N | AML18 TRIAL | 101683139 |
| 240002702 | 240002702 | null | null | null | null | 2018-02-21 | AML 18 TRIAL | null | null | METHOTREXATE | 101607922 |
| 240002705 | 240002705 | 1.62 | 74 | null | 2017-07-29 | 2017-07-29 | null | 02 | N | AML18 TRIAL | 100174880 |
| 240002713 | 240002713 | null | null | null | null | 2019-01-23 | null | null | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 101505629 |
| 240002716 | 240002716 | 1.66 | 64.7 | 03 | null | 2017-05-30 | null | 02 | N | BORTEZOMIB + THALIDOMIDE | 100664609 |
| 240002718 | 240002718 | 1.62 | 125.2 | 03 | null | 2017-02-06 | Hydroxycarbamide | 02 | N | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE | 100357576 |
| 240002725 | 240002725 | 1.63 | 85.6 | Curative (C) | 2017-01-17 | 2017-01-17 | null | 02 | N | FCR | 101098146 |
| 240002733 | 240002733 | 1.76 | 55.5 | Curative (C) | 2018-08-18 | 2018-08-19 | Cytarabine Low Dose | 02 | N | CYTARABINE + FLUDARABINE + IDARUBICIN | 101528355 |
| 240002734 | 240002734 | 1.64 | 110 | Curative (C) | 2018-10-18 | 2018-10-18 | FLAG | 02 | null | GEMTUZUMAB OZOGAMICIN | 100505346 |
| 240002736 | 240002736 | 1.65 | 91 | Curative (C) | null | 2016-12-23 | CYTARABINE + DAUNORUBICIN | 02 | N | BENDAMUSTINE + RITUXIMAB | 100452598 |
| 240002739 | 240002739 | null | null | null | null | 2019-06-19 | DA | null | null | AML18 TRIAL | 100407138 |
| 240002746 | 240002746 | 1.68 | 25.7 | Adjuvant (A) | null | 2019-11-22 | null | N | N | CYCLOPHOSPHAMIDE + CYTARABINE + DOXORUBICIN + METHOTREXATE + RITUXIMAB + VINCRISTINE | 101093915 |
| 240002748 | 240002748 | null | null | null | null | 2017-06-23 | null | null | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 101382170 |
| 240002752 | 240002752 | null | null | Disease modification (D) | 2019-05-31 | 2019-05-31 | NHL 2003 Gp B COP | null | N | CLADRIBINE | 101242258 |
| 240002761 | 240002761 | 1.68 | 104.2 | 03 | null | 2017-04-29 | null | 1 | N | AML18 TRIAL | 101043271 |
| 240002762 | 240002762 | null | null | null | null | 2017-08-27 | null | null | null | AML19 TRIAL | 101334283 |
| 240002763 | 240002763 | null | null | null | null | 2017-11-29 | null | null | null | IDARUBICIN + TRETINOIN | 100590853 |